Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Example vaccine vial in clinic © John Cairns
  • Primary analysis, part of pre-specified trial protocol, follows interim analysis on Monday 22 March
  • Data are consistent with interim analysis, and will form submission by AstraZeneca to US FDA
  • Vaccine 76% effective against symptomatic COVID-19, and 100% effective against severe or critical disease and hospitalisation

This primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis.

In addition, results were comparable across age groups, with vaccine efficacy of 85% in adults 65 years and older. A key secondary endpoint, preventing severe or critical disease and hospitalisation, demonstrated 100% efficacy.

Read the full story on the University of Oxford website.

Similar stories

Children and Adolescents’ Mental Health: One Year On

Coronavirus COVID-19 General Research

Parents and carers reported that behavioural, emotional and attentional difficulties in their children changed considerably throughout the past year, increasing in times of national lockdown and decreasing as restrictions eased and schools reopened, according to the latest Co-SPACE (COVID-19 Supporting Parents, Adolescents, and Children in Epidemics) study, led by experts at the University of Oxford.

Tackling climate concerns through sustainable healthcare

General

A new initiative by Oxford Medical Students and faculty is accelerating the learning of sustainable healthcare at Oxford.

Promising malaria vaccine enters final stage of clinical testing in West Africa

Clinical Trials General Research

First vaccinations have now begun in Mali in a phase III trial of a malaria vaccine developed at the University of Oxford. Known as R21/Matrix-M, it recently showed efficacy of 77% over 12 months in a phase IIb trial, and it is hoped that this phase III trial will help to lead to licensure of this malaria vaccine by 2023.

Oxford researchers elected to Royal Society

Awards and Appointments General

Six scientists from the University of Oxford, including Professor Adrian Hill and Professor Frances Platt from the Medical Sciences Division, have joined the Royal Society as Fellows.

Student Prizes for Biomedical Sciences and Medicine 2020-2021

Awards and Appointments General

Congratulations to all our Biomedical Sciences students and Medicine students who have been awarded prizes during the 2020-2021 academic year.

Multi-partner 'OpenMind' consortium to develop technology for new generation of neurostimulation devices

General Research

Investigators at the University of Oxford, University of California San Francisco (UCSF), Brown University and the Mayo Clinic have joined forces to develop open-source technology platforms for a new generation of neurostimulation devices that not only provide stimulation to the brain but also sense, record, and stream brain activity.